Department of Pediatrics, Texas Tech University Health Sciences Center School of Medicine, Lubbock, TX 79430, USA.
Department of Physiology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.
Medicina (Kaunas). 2020 May 7;56(5):224. doi: 10.3390/medicina56050224.
The majority of pediatric patients are cured of their primary cancer with current advanced developments in pediatric cancer therapy. However, survivors often experience long-term complications from therapies for primary cancer. The delayed mortality rate has been decreasing with the effort to reduce the therapeutic exposure of patients with pediatric cancers. Our study investigates the incidence of sarcoma as second cancer in pediatric cancer survivors. We present a 9-year-old male who survived embryonal hepatoblastoma diagnosed at 22 months of age. At 4.5 years of age, he presented with a non-metastatic primitive neuroectodermal tumor (PNET) of the left submandibular area. He has no evidence of recurrence of either cancer for 51 months after finishing all chemotherapy and radiotherapy. We used the Surveillance, Epidemiology, and End Results (SEER) database to identify the current rate of second sarcomas in pediatric cancer survivors. Our literature review and large population analysis emphasize the impact of sarcoma as a second malignancy and provide help to physicians caring for pediatric cancer survivors.
大多数儿科患者通过当前先进的儿科癌症治疗方法治愈了原发性癌症。然而，幸存者经常因原发性癌症的治疗而出现长期并发症。随着努力减少儿科癌症患者的治疗暴露，延迟死亡率一直在下降。我们的研究调查了肉瘤作为儿科癌症幸存者的第二癌症的发病率。我们介绍了一位 9 岁男性，他在 22 个月大时被诊断患有胚胎性肝母细胞瘤而幸存下来。在 4.5 岁时，他出现了左侧下颌区域的非转移性原始神经外胚层肿瘤（PNET）。在完成所有化疗和放疗后 51 个月，他没有任何癌症复发的迹象。我们使用监测、流行病学和最终结果 (SEER) 数据库来确定儿科癌症幸存者中当前第二肉瘤的发生率。我们的文献回顾和大人群分析强调了肉瘤作为第二恶性肿瘤的影响，并为照顾儿科癌症幸存者的医生提供了帮助。
